Closer look at TAILORx confirms lack of chemo benefit regardless of race or ethnicity

Before TAILORx, there was uncertainty about treatment for women with hormone receptor-positive, HER2-negative, node-negative breast cancer and a score of 11-25 on a tumor gene test. The trial was designed to address this question and provides a definitive answer: no benefit from chemotherapy for women over 50 with a score of 11-25; 50 years old or younger with a score of 11-15; and any age with a score of 0-10.

Go to Source

(Visited 1 times, 1 visits today)

Site Footer

Sliding Sidebar